Precision Medicine in Oncology®

Nathan Pennell, MD, PhD, offers strategies regarding molecular testing in patients with lung cancer and how to address treatment if patients are symptomatic and molecular testing results are unavailable.

Jonathan W. Goldman, MD, health sciences clinical instructor, Department of Medicine, and Hematology/Oncology member, Jonsson Comprehensive Cancer Center Signal Transduction and Therapeutics Program, UCLA, discusses the use of immunotherapy in patients with oncogene-driven non–small cell lung cancer (NSCLC).

Hatim Husain, MD, medical oncologist and associate professor of medicine, Moores Cancer Center, University of California, San Diego (UCSD), discusses ongoing research efforts evaluating plasma-based testing in lung cancer.

Gopa Iyer, MD, discusses investigational FGFR inhibitors in metastatic urothelial carcinoma.

Gregory A. Otterson, MD, discusses targetable biomarkers in non–small cell lung cancer.

Lynette M. Sholl, MD, discusses the challenges faced with the use of tissue biopsy to test for biomarkers in lung cancer.

Driven by advances in genetic testing methods and the discovery of actionable mutations beyond BRCA, an update to the National Comprehensive Cancer Network’s Guidelines for genetic testing in breast, ovarian, and pancreatic cancers encompasses a much broader range of genes that predict risk for disease occurrence.

Richard S. Finn, MD, discusses biomarkers of response to immunotherapy in hepatocellular carcinoma.

Gopa Iyer, MD, discusses treatment-emergent hyperphosphatemia with erdafitinib in patients with metastatic urothelial cancer.

Anastasios (Tassos) Dimou, MD, discusses the limitations of tumor mutational burden as a biomarker in lung cancer.

David Polsky, MD, PhD, discusses the unmet need of clinical utility in liquid biopsy.

Single-agent cisplatin did not lead to significantly higher pathologic complete response rates or improved residual cancer burden scores compared with doxorubicin plus cyclophosphamide in the neoadjuvant setting for patients with stage I to III HER2-negative breast cancer who harbor BRCA mutations.

Andrea Sboner, MS, PhD, assistant professor of computational genomics in computational biomedicine and of pathology and laboratory medicine, Weill Cornell Medicine, discusses the applications of a mixed reality laboratory.

Larotrectinib continued to show strong tumor-agnostic efficacy in patients with TRK fusion–positive cancers, according to results from an integrated analysis of 3 clinical trials.

Hatim Husain, MD, discusses the increased use of and challenges with utilizing liquid biopsies.

Researchers at the Mayo Clinic maintain that all women aged 65 or under with a breast cancer diagnosis should receive germline genetic testing to identify harmful mutations that increase their risk of developing secondary cancers.

Jonathan W. Goldman, discusses the impact of liquid biopsies in lung cancer.

Patients with breast cancer who are ultrarapid or poor CYP2D6 metabolizers of tamoxifen have a worse prognosis compared with normal metabolizers after receiving a standard dose of the drug, due, in part, to a higher incidence of treatment-related adverse events.

Jonathan W. Goldman, MD, discusses the current landscape of biomarker-driven lung cancer.

Jean Lopategui, MD, associate professor of pathology and director of Translational Genomics and of the Molecular Genetics Pathology Fellowship at Cedars-Sinai, discusses the implications of genomic sequencing in lung cancer.

Hatim Husain, MD, discusses the current state of liquid biopsy in non–small cell lung cancer.